Performance of AstraZeneca Stock in 2Q17



A look at AstraZeneca

Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in more than 100 countries. The company is involved in research and development and manufacturing drugs for both primary and specialty care.

Article continues below advertisement

Stock price performance

AstraZeneca stock has risen ~10.5% in 2Q17, while it has risen ~23.1% year-to-date as of July 7, 2017.

Analyst recommendations

Wall Street analysts estimate that AstraZeneca stock has the potential to return ~1.4% over the next 12 months. They show a 12-month target price of $34.12 per share compared to the last price of $33.64 on July 6, 2017.

There are 35 analysts tracking AstraZeneca stock. Of those, 20 analysts are recommending a “buy,” 12 are recommending a “hold,” and three are recommending a “sell.” The consensus rating for AstraZeneca is 2.3, which represents a “strong buy” for value investors as well as a “moderate buy” for long-term growth investors.

Analysts’ revenue estimates

AstraZeneca’s revenues are mainly driven by the strong performance of its growth platforms, which include a few of the segments as well as a few of the regions. These segments and regions are respiratory products, new cardiovascular and metabolic diseases products, new oncology products, and regional sales from emerging markets and Japan.

Wall Street analyst estimates show revenues of $5.2 billion in 2Q17, a ~7.6% fall compared to 2Q16, and EPS (earnings per share) of $0.85 for the quarter.

To divest the company-specific risks, you can consider the Vanguard FTSE Europe ETF (VGK), which holds 1.0% of its total assets in AstraZeneca. VGK also holds 1.2% in Novo Nordisk (NVO), 1.3% in Sanofi (SNY), and 1.3% in GlaxoSmithKline (GSK).


More From Market Realist